Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report published on Friday. The firm issued a sell rating on the stock.

Other equities research analysts have also issued reports about the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, December 31st. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Stock Up 0.6 %

Shares of CANF opened at $1.58 on Friday. The stock has a market cap of $5.59 million, a PE ratio of -0.88 and a beta of 1.36. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The business has a 50-day simple moving average of $1.80 and a two-hundred day simple moving average of $2.32.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.